What is Zacks Research’s Estimate for Teleflex Q3 Earnings?

Teleflex Incorporated (NYSE:TFX) – Zacks Research issued their Q3 2025 EPS estimates for Teleflex in a research report issued to clients and investors on Wednesday, August 13th. Zacks Research analyst Team anticipates that the medical technology company will earn $3.38 per share for the quarter. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q4 2025 earnings at $4.02 EPS, FY2025 earnings at $14.04 EPS, Q1 2026 earnings at $3.07 EPS, Q2 2026 earnings at $3.74 EPS, Q3 2026 earnings at $4.10 EPS, Q4 2026 earnings at $3.46 EPS, FY2026 earnings at $14.38 EPS, Q1 2027 earnings at $4.03 EPS, Q2 2027 earnings at $3.88 EPS and FY2027 earnings at $16.35 EPS.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same period in the prior year, the business posted $3.42 earnings per share. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada upped their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “sector perform” rating in a report on Friday, August 1st. Truist Financial reduced their price target on shares of Teleflex from $140.00 to $137.00 and set a “hold” rating on the stock in a report on Monday, May 5th. Wells Fargo & Company reduced their price target on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Wall Street Zen raised shares of Teleflex from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Finally, Mizuho upped their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a report on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $141.57.

Teleflex Trading Down 0.4%

Shares of TFX opened at $121.00 on Friday. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average is $117.93 and its two-hundred day moving average is $132.81. Teleflex has a twelve month low of $108.90 and a twelve month high of $249.90. The firm has a market capitalization of $5.35 billion, a P/E ratio of 28.47, a PEG ratio of 1.69 and a beta of 1.08.

Teleflex Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. Teleflex’s dividend payout ratio is presently 32.00%.

Insider Buying and Selling at Teleflex

In other news, CEO Liam Kelly acquired 1,500 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average price of $115.07 per share, with a total value of $172,605.00. Following the completion of the purchase, the chief executive officer owned 45,267 shares of the company’s stock, valued at approximately $5,208,873.69. This represents a 3.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stuart A. Randle acquired 1,000 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were purchased at an average cost of $115.86 per share, for a total transaction of $115,860.00. Following the purchase, the director directly owned 7,547 shares of the company’s stock, valued at approximately $874,395.42. This trade represents a 15.27% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 5,500 shares of company stock valued at $633,590. 1.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Teleflex

Several institutional investors and hedge funds have recently modified their holdings of TFX. Norges Bank acquired a new position in Teleflex during the second quarter worth approximately $65,826,000. Pzena Investment Management LLC acquired a new position in Teleflex during the second quarter worth approximately $42,149,000. Dimensional Fund Advisors LP increased its position in Teleflex by 69.5% during the first quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company’s stock worth $119,927,000 after purchasing an additional 355,720 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in Teleflex by 122.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company’s stock worth $80,784,000 after purchasing an additional 322,222 shares during the last quarter. Finally, Invenomic Capital Management LP increased its position in Teleflex by 1,400.1% during the first quarter. Invenomic Capital Management LP now owns 344,732 shares of the medical technology company’s stock worth $47,639,000 after purchasing an additional 321,751 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.